Rapid resolution of pyoderma gangrenosum with brodalumab therapy

Abstract

Pyoderma gangrenosum (PG) is a burdensome ulcerative dermatosis, which presents in isolation or in association with other inflammatory conditions (eg, inflammatory bowel disease).1 PG can be therapeutically challenging, especially when first-line treatments (such as oral corticosteroids and cyclosporine) fail to resolve the condition.1,2 Although interleukin (IL)-17 and IL-23 antagonism may ameliorate disease activity, only case reports of secukinumab therapy currently exist.2 We report 2 cases of PG that showed rapid resolution in response to brodalumab, 210 mg/1.5 mg, for co-existing hidradenitis suppurativa (HS).

Topics & Concepts